News for Recursion Pharmaceuticals, Inc. (RXRX)

Recursion (RXRX) is set to unveil initial findings from its ongoing TUPELO clinical trial at the 2025 Digestive Disease Week conference. This Phase 1b/2 trial i

Recursion Pharmaceuticals (RXRX) reachead $5.41 at the closing of the latest trading day, reflecting a -1.64% change compared to its last close.

Recursion (RXRX) has entered into a strategic licensing agreement with HealthVerity to incorporate its comprehensive real-world data into Recursion's clinical t

\n Recursion (RXRX) partners with HealthVerity to enhance clinical trial capabilities with real-world data. Access to de-identified data covering 340 milli

We recently published a list of Tech Firms Dominate Monday’s 10 Worst Performers.

Several biotech firms are witnessing significant upticks in search interest, highlighting growing investor attention. Leading the surge is Theratechnologies (TH

Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands against other firms that defied the market slump and recorded double-digit gains last week. The stock market may have taken a beating […]

We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc.

We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks.

Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. Read my RXRX stock thesis.

Recursion Pharmaceuticals (RXRX) has experienced a notable uptick in options trading, driven by increased demand for call options. A total of 9,589 call contrac

U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday. Shares of Fastenal Company FAST rose sharply during Thursday's session foll...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-i...

Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies. Two AI healthcare stocks -- Recursion Pharmaceuticals (NASDAQ: RXRX) and Teladoc Health (NYSE: TDOC) -- have lagged the market over the past year.

Next week, investors should keep an eye on Quantum Computing (QUBT) and Sunnova Energy International (NOVA) as options trading indicates heightened volatility.

“There’s an AI biotech selling for just $7 a share that seems poised to soar in 2025… “ARK Investment recently bought almost 7 million shares… “Baye...

We recently published a list of Pulse of The Market: Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc.